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Abstract 
Purpose This study aimed to explore the impact of an 8 year therapy with autoadjusting positive airway 
pressure (APAP) on fasting lipid level in a sample of Portuguese moderate/severe OSA patients. Besides 
contributing to the comprehension of the complex relationship between dyslipidemia and OSA, it 
provided new data regarding the effectiveness of a long term APAP treatment. 
Methods Thirty-nine male patients with moderate to severe OSA were included in the study. APAP was 
prescribed to all patients. Fifteen patients were under lipid-lowering medication throughout the study and 
another fifteen patients never used lipid-lowering medication at any time during the study. Fasting 
morning venous blood samples were collected at three time points (baseline, 6 months and 8 years) and 
lipids were estimated. Statistical analysis was performed using Statistical Package for the Social Sciences 
(SPSS) 21.0 software. 
Results After 8 years of APAP treatment, patients presented a similar body mass index but a significantly 
less severe daytime sleepiness. Patients on lipid-lowering medication exhibited a higher reduction in 
LDL-c, triglycerides and total cholesterol than those naïf from that medication, but the reduction was not 
statistically significant after adjusting for medication and APAP adherence.   
Conclusions Long-term APAP treatment improves OSA but does not seem to contribute to changes in 
fasting lipids.  
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Introduction 
Obstructive sleep apnea (OSA) is one of the most important medical conditions identified in the last 50 
years , and  it has been defined as a respiratory disorder with cardio-metabolic implications [1, 2]. 
 Although it occurs in all age groups, it is most often found among 40-60 years old and according to a 
recent study [3] the prevalence rates in the middle-aged adults have risen substantially in recent decades 
(13% of men and 6% of women have moderate to severe sleep disordered breathing).  
Besides OSA is a common disorder, it is a major cause of morbidity and significant cause of mortality [4-
8] and the most common cause of daytime sleepiness [9, 10]. 
Patients with OSA have higher cardiovascular risk than general population [11] and cumulating evidence 
over the years has been shown the complex relationship between OSA and cardiovascular risk factors 
including obesity, hypertension, insulin resistance, impaired glucose tolerance and dyslipidemia, which 
together comprise the metabolic syndrome [12, 16]. OSA has also been shown to be independently 
associated with atherosclerotic disease [17].  
OSA patients have an increased risk of proatherogenic dyslipidemia [11, 18], which is, frequently 
associated with reduced high-density lipoprotein cholesterol (HDL-C) and raised triglycerides (TGs), 
low-density lipoprotein cholesterol (LDL-C) and total cholesterol plasma levels [19, 20]. Although a cut 
clean causal relationship between OSA and dyslipidemia is yet to be established, growing body of 
evidence and underlying mechanisms have been proposed suggesting a strong association [15]. 
Continuous positive airway pressure (CPAP) is the standard option for treatment of OSA [21, 22]. It 
eliminates upper airway narrowing, reduces daytime sleepiness, increases alertness and improves quality 
of life [23]. Moreover, CPAP also was shown to reduce cardiovascular morbility through alterations of 
each of the components of metabolic syndrome [14, 16, 24]. Auto-adjusting positive airway pressure 
(APAP) devices are an alternative treatment to traditional CPAP and are able to improve symptoms [25] 
with the advantage of increasing long-term treatment compliance [26]. However, the impact of APAP 
treatment on lipid profile of OSA patients is far from being ascertained. Not only the studies are 
inconsistent but also they are limited in duration of follow-up [14, 16, 22, 24, 27-35].  
The study here proposed aims to evaluate the long term APAP impact on lipid profile in a convenience 
Portuguese sample of patients with moderate/severe OSA diagnosed, treated and followed for the last 8 
years.  
Methods 
Study design 
This is a prospective observational study. Written informed consent was obtained from each participant. 
The study protocol was approved by the Hospital Ethics Committee and performed accordingly in 
agreement with the Helsinki Declaration of 1975, as revised in 1983.  
Subjects  
Thirty nine male patients, referred to our Sleep Disordered Breathing Outpatient Clinic, 8 years ago with 
newly diagnosed moderate/severe OSA (AIH > 15 events/h), confirmed previously [31] by domiciliary 
cardio-respiratory sleep study, were included in the study. Fifteen patients have been using lipid-lowering 
medication throughout the study (from baseline up to 8 years) and another fifteen patients never used 
lipid-lowering medication at any time point during the study. Seven patients were not on lipid-lowering 
medication at the beginning or at 6 months of the study but started the medication after. Two were on 
lipid-lowering medication but discontinued medication over time.  
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Exclusion criteria were established previously: neoplastic diseases, systemic inflammatory chronic 
diseases, active infectious diseases, systemic long-term corticotherapy and weight loss greater than 10%. 
Body mass index (BMI) was calculated by the formula weight/height2.  
Study procedures 
The patients here included have been on APAP therapy (REMstarTM Auto, Respironics Inc., Murrysville, 
PA, USA) during the past 8 years. APAP therapy was prescribed to all patients with a pre-determined 
minimum and maximum pressure of 4 and 18 cmH20, respectively. Concerning therapy effectiveness, a 
periodic every six-month follow-up was conducted, with evaluation of clinical symptoms (by Epworth 
sleepiness scale (ESS)) and APAP compliance variables (number of hours per night, percentage of total 
days of APAP usage, residual Apnea Hypopnea Index (AHI) based on objective data downloaded from 
APAP memory cards. 
Adherent patients were those using positive airway pressure therapy for ≥ 6 h per night and for ≥ 20 of 
the last 28 nights based on the usage data from memory cards [36]. 
Fasting morning venous blood samples were collected at three time points: in untreated patients at 
baseline, after 6 months of treatment and after 8 years of treatment. Blood samples were collected 
between 8 and 10 a.m. after a 12 hours period of fasting. Blood samples were immediately sent to the 
laboratory for estimation of lipids level (HDL-c,LDL-c, triglycerides and total cholesterol,). Indicators of 
“abnormal” levels were defined using the National Cholesterol Education Program (NCEP) Adult 
Treatment Panel III (ATPIII) criteria [37] : HDL-c <40mg/dL; LDL-c ≥130 mg/dL; triglycerides 
≥150mg/dL and total cholesterol ≥ 200mg/dL.  
Statistical analysis 
Data analysis was performed using the Social Sciences (SPSS Inc., Chicago, Illinois, USA), 21.0 software 
version. All probabilities were two-tailed and p values <0.05 were regarded as significant.  
Data were described as mean and standard deviation (SD) for quantitative variables.  For comparison of 
quantitative variables the Student’s t test and Mann-Whitney test were used. The Chi-square test or the 
Fisher exact test used to compare categorical variables whenever was appropriate. For comparison 
between median values at the three moments studied the non parametric Wilcoxon test for paired samples 
was used.  
Associations between the use of lipid-lowering medication and number of hours per night of APAP usage 
were assessed using multivariate general linear regression model. 
Results 
Thirty-nine male voluntary patients (n=39) participated in the study. All of them had moderate-to-severe 
OSA at the beginning of the study (baseline; n=4 moderate OSA; n=35 severe OSA). Overall studied 
population characteristics at baseline are presented in Table 1.  
After 8 years of APAP treatment the group mean age was 64.36 years (SD = 9.57 years), with ages 
ranging between 38 and 81 years old. Characteristics of participants considering body mass index (BMI), 
use of lipid-lowering medications, ESS, AHI and therapy adherence at baseline and after 8 years are 
shown in Table 2.  
The severity of day time sleepiness (evaluated by ESS) was significantly decreased after 8 years of APAP 
usage (11.0 versus 2.6; p<0.01). 
Although the percentage of total days of APAP usage did not significantly differ between 6 months and 8 
years, there was a significantly increased in the number of hours/night of APAP usage between both 
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groups. The mean number of hours/night of APAP usage at 6 months was 6.15 (±1.31) with a minimum 
and maximum hours/night of 3.05 and 8.23, respectively. At 8 years the mean number of hours/night of 
APAP usage was higher amounting 7.10 (±1.00) with a minimum and maximum hours/night of 4.55 and 
9.11, respectively.  
During the 8 years of APAP treatment, patients had their HDL-c levels decreased from 0.50 g/dL (SD 
0.1g/dL) at baseline to 0.46 g/dL (SD 0.1 g/dL; p<0.01) after 8 years. Similarly, both triglycerides (TG) 
and total cholesterol levels also decreased significantly [1.70 g/dL (SD 0.7 g/dL) versus 1.40 g/dL (SD 
0.8 g/dL); p=0.04 and 2.00 g/dL (SD 0.5 g/dL) versus 1.69 g/dL (SD 0.3 g/dL); p<0.01, respectively], 
although no changes were observed regarding LDL-c levels [(1.08 g/dL (SD 0.4 g/dL) versus 0.99 g/dL 
(SD 0.3 g/dL); p=0.17]. At baseline, 17 patients were under lipid-lowering medication and that number 
increased up to 22 patients at 8years.  
We next evaluate the variation of HDL-c, LDL-c, TG and total cholesterol levels along time using two 
subgroups: those since the beginning of the study were under lipid-lowering medication (n=15) and those 
that never used any lipid-lowering medication (n=15). We observed that there was a statistically 
significant reduction in the LDL, TG and total cholesterol levels among those who were under lipid-
lowering medication that was not shown in the other group (Table 3).  
In order to understand if this reduction could be explained by the use of lipid-lowering medication alone 
and/or by the use of APAP we performed a multivariate general linear model analysis (Table 4). After 
adjustments, the results suggest that those patients who did lipid-lowering medication throughout 8 years 
exhibited a higher reduction in total cholesterol levels than those who did not but the reduction was not 
statistically significant. In addition, the higher number of hours/night APAP usage indicated that there 
was an increase in the levels of HDL-C but again no significant association was found. 
Discussion 
OSA is increasingly considered as a risk factor for metabolic disturbances, such as dyslipidemia [11, 18]. 
Several observational and uncontrolled clinical studies allege an improvement of the metabolic variables, 
lipids included, through the use of positive airway pressure [24, 31, 38-40]. These investigators reported a 
small, but statistically significant change in the lipid profile of OSA patients, hence beneficial effects of 
CPAP treatment in selected patient cohorts cannot be excluded.  
However, only a limited number of clinical randomised controlled trials (RCTs) have until now evaluated 
the effect of CPAP on lipids [22, 28, 32, 41-43]. Of these six, only one [32] found significant reductions 
in total cholesterol and triglycerides. Curiously, none of the others RCTs have examined lipids as a 
primary outcome. Phillips et al. calculated means of seven blood samples during 24 hours, whereas other 
authors used standard fasting lipid tests. Sharma et al. [44] conducted a randomised controlled crossover 
trial, showing decreases in cholesterol, but it was retracted.  
The main goal of the present study was to investigate the effect of long-term APAP treatment on lipid 
profile of moderate-to severe OSA patients.  
Although a significant reduction in triglycerides and total cholesterol levels was found among the overall 
sample, between baseline and 8 years, this reduction could not be directly attribute to long-term APAP 
usage since some of the patients were under lipid-lowering drugs. These drugs are most effective in 
dyslipidemia treatment and, conceivably, could mask the effect of OSA on fasting lipids, but no studies 
have shown whether these pharmacotherapeutic approaches are equally efficacious in patients with OSA. 
Indeed, when comparing two subgroups of patients, those who have been always on lipid-lowering drugs 
and those that never did this medication, the statistically reduction in triglycerides and total cholesterol 
levels is most likely accounted for by the treated subgroup. Evidently, the majority of patients not under 
lipid-lowering treatment do not have dyslipidemia and, in the few with abnormal lipids, we could not 
observe any differences in lipid changes at 8 years (data not shown). It is important to mention, that only 
five patients started de novo lipid-lowering medication during the study and the variation of dyslipidemia 
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did not concur with the inaugural institution of lipid-lowering medications.  Also noteworthy are the 
additional positive airway pressure benefits related to neurocognitive and sleepiness improvements that 
we are not aware any lipid-lowering medication could provide. Ultimately, the best scenario would be to 
perform this analysis in OSA untreated dyslipidemic patients but it would be unethical to deliberately 
prevent these patients from its treatment.  
Nonetheless, after adjustments for all relevant covariates (lipid-lowering drugs and APAP adherence), we 
were not able to discriminate a statistically significance that could explain the reduction in triglycerides 
and total cholesterol in the patients under lipid-lowering medication. In fact, it seems that lipid-lowering 
drugs could not per se explain the changes observed on triglycerides and total cholesterol. We have to 
consider the size of our sample and other covariates not taken in account that may justify this outcome. 
This is also valid for the adjustment using number of hours/night of APAP. Although it was observed that 
lipid-lowering medicated patients used more hours/night of APAP we can always speculate that these are 
more aware of their disease and thus more adherent to treatment.  APAP better usage could not also 
explain the lipid effect.  
Several studies have associated OSA with a decrease in HDL-c [30, 45, 46]. HDL is anti-atherogenic and 
has anti-oxidant, anti-inflammatory and anti-coagulant properties [47] but may become pro-oxidant and 
pro-inflammatory under special circumstances [48, 49]. Tan et al. [50] have shown that the increase in 
oxidative stress in subjects with OSA is associated not only with increased lipid peroxidation but is also 
associated with HDL dysfunction, which may in part contribute to the increased cardiovascular risk of 
these subjects. We found out that there is a significant decrease on HDL-c levels despite the use of lipid-
lowering drugs after long-term APAP, although after multivariate analysis it seems to have a trend of 
increase in the most adherent patients.  
Since our population is heterogeneous regarding age, marital status, socioeconomic status and 
psychological factors it does not seem possible that these variables can interfere in the results obtained.  
It is known that the pattern of adherence to positive airway pressure therapy is established as early as 3 
days following CPAP initiation and predicts long-term use [51]. In addition, it is possible that the 
compliance here observed might be related to the symptomatic severity expressed initially, which is 
known to be a stronger support to influence adherence [52, 53]. Moreover, this outcome does not seem to 
be related to weight since we could not observe any effect of long-term APAP in BMI. Contrary to other 
recent studies [35, 54], where adherent patients had an average increase in BMI of 1 kg.m-2 over follow-
up, we could not observe an increase in our patients BMI. It has been suggested that OSA patients have 
an increase in their energy expenditure and that positive airway pressure reduces this expenditure, by an 
unclear mechanism [54, 55]. Not only did they not increase in weight but also the reduction of OSA 
severity does not seem to be related to weight loss, as observed by Teramato et al. [56].  
Our study has strengths and some limitations. To the best of our knowledge this is the longest study to 
date exploring the relationship between APAP long-term therapy and fasting lipids in a moderate-to-
severe OSA population. The moderate-to-severe OSA Portuguese patients here used were a male 
Caucasian heterogeneous population that we would expect to be similar to others of similar ethnicity 
throughout the world. We could not exclude the possibility that results may be different depending on the 
ethnicity. Moreover, results only reflect a male moderate-to-severe OSA population. It is known that the 
influence of sex is particularly important given the higher cardiovascular risk associated with lipidemia in 
females and it would be interesting to study the potential of sex to modify the effect. The here used 
sample is small and we recognise the potential for presently unknown or unmeasured confounders to 
influence the results. Although the blood samples were collected after a 12 hours fasting period we could 
not control the effect of meal composition the day before the blood samples were collected. It is also 
arguable to use only one time period to perform the blood collections, a calculated means of several blood 
samples would be better but would be time consuming and not appreciated by the patients. A possible 
limitation is that it was not a randomized controlled trial, but such a study is not easy to perform since it 
would be unethical to leave patients with confirmed OSA and dyslipidemia untreated. 
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Though a direct cause and effect relationship between OSA and dyslipidemia is yet to be established, 
there is a significant and growing body of evidence that a strong association exists [15] (Adedayo et al., 
2012). Simultaneously, our data is in keeping with a very recently published study [35] (Keenan et al., 
2014) where it was shown that positive airway pressure does not significantly affects fasting lipid levels 
after 2 years APAP treatment. To clarify the actual impact of positive airway pressure on total cholesterol 
and other lipids, large RCTs with carefully selected patients are warranted.  
In summary, long-term APAP treatment improves OSA but does not seem to contribute to changes in 
fasting lipids.  
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Table 1: Sample characteristics at baseline 
 VARIABLE
*
 BASELINE n=39 
           AGE (years) 56.4 (9.57)  
            BMI (kg/m2) 33.6 (5.20)  
 ESS 10.6 (6.00)  
               AHI (events/h) 51.9 (19.6)  
          SMOKING HABITS n (%)   
 NON-SMOKERS 18 (46.2)  
 FORMER SMOKERS 18 (46.2)  
 SMOKERS   3 (7.70)  
BMI body mass index, ESS Epworth sleepiness scale, AHI apnea/hypopnea 
index  
 * Quantitative variables are expressed as mean and standard deviation (SD)  
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Table 2: Sample characteristics at the three evaluated stages: baseline, 6 months and 8 years  
VARIABLE
*
 BASELINE 6 MONTHS 8 YEARS 
 
p value 
         
n=39 
           BMI (kg/m2) 33.6(5.2) --       33.0(4.6) 0.36  
ESS 11.0(6.0) -- 4.6(3.2)    0.00**  
              AHI (events/h)   52.6(19.4) --         2.6(1.3)    0.00**  
TOTAL DAYS APAP USAGE (%) -- 94.9(12.1)       98.3(3.1) 0.11  
      APAP HOURS PER NIGHT -- 6.23(1.23)        7.09(1.0)    0.00**  
                    HDL-C 0.50(0.1) --  0.46(0.1)    0.01**  
                    LDL-C 1.08(0.4) --  0.99(0.3)           0.17  
      TOTAL CHOLESTEROL 2.00(0.5) --  1.69(0.3)   0.00**  
                    TG 1.70(0.7) --  1.40(0.8)  0.04*  
 BMI body mass index, ESS Epworth sleepiness scale, AHI apnea/hypopnea index, APAP autoadjusting positive airway 
pressure, HDL-C high-density lipoprotein cholesterol, LDL-C low-desnsity lipoprotein cholesterol, TG triglycerides * 
Quantitative variables are expressed as mean and standard deviation (SD) **p < 0.01 *p < 0.05 
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Table 3: Baseline and 8 years characteristics of patients under lipid-lowering drugs and patients without 
lipid-lowering drugs treatment within the sample 
VARIABLE
*
 
LIPID-LOWERING DRUGS 
n=15 
NO LIPID-LOWERING DRUGS 
n=15 
 
MEAN(SD) 
BASELINE 
MEAN(SD) 
8 YEARS 
p value 
MEAN(SD) 
BASELINE 
MEAN(SD) 
8 YEARS 
p value 
HDL-C 0.53(0.19) 0.47(0.13) 0.039* 0.45(0.67) 0.43(0.77) 0.049* 
LDL-C 0.93(0.32) 0.84(0.29) 0.397 1.23(0.31) 1.10(0.30) 0.222 
TOTAL CHOLESTEROL 1.86(0.44) 1.57(0.28) 0.008** 2.02(0.40) 1.77(0.32) 0.031* 
TG 1.75(0.82) 1.48(0.99) 0.191 1.67(0.69) 1.39(0.85) 0.125 
           BMI (kg/m2) 33.3(4.02) 31.9(3.54) 0.038* 34.0(6.20) 33.2(4.67) 0.334 
              AIH (events/h) 42.4(16.0) 2.66(1.49) 0.001** 58.4(21.9) 2.36(1.19) 0.001** 
Wilcoxon Signed Ranks Test (non-parametric test) BMI body mass index, ESS Epworth sleepiness scale, AHI apnea/hypopnea index, HDL-C 
high-density lipoprotein cholesterol, LDL-C low-desnsity lipoprotein cholesterol, TG triglycerides * Quantitative variables are expressed as 
mean and standard deviation (SD) **p < 0.01 *p < 0.05  
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Table 4: Differences in 8-year fasting lipid changes after adjustment for lipid-lowering medication and 
number of hours/night of APAP. Data collected after a multivariate general linear model analysis 
  
VARIABLE LIPID LOWERING DRUGS APAP 
 NON-ADJUSTED ADJUSTED NON-ADJUSTED ADJUSTED 
 
MEAN 
DIFFERENCE 
95% 
CI 
p 
value 
MEAN 
DIFFERENCE 
95% 
CI 
p 
value 
MEAN 
DIFFERENCE 
95% 
CI 
p 
value 
MEAN 
DIFFERENCE 
95% 
CI 
p 
value 
HDL-C 0.03 
-0.33 
0.10 
0.30 0.03 
-0.02 
0.12 
0.37 -0.04 
-0.17 
0.09 
0.51 -0.04 
-0.16 
0.13 
0.57 
LDL-C 0.04 
-0.25 
0.32 
0.79 -0.01 
-0.29 
0.28 
0.94 -0.24 
-0.73 
0.26 
0.35 -0.23 
-0.75 
0.27 
0.35 
TC 0.09 
-0.47 
0.66 
0.73 0.11 
-0.45 
0.68 
0.69 -0.69 
-1.80 
0.33 
0.18 -0.68 
-1.71 
0.36 
0.19 
TG 0.23 
-0.66 
0.52 
0.12 0.19 
-0.10 
0.50 
0.19 -0.29 
-0.84 
0.26 
0.29 -0.26 
-0.80 
0.29 
0.34 
HDL-C high-density lipoprotein cholesterol, LDL-C low-desnsity lipoprotein cholesterol, TC total cholesterol, TG triglycerides, 95%CI 
confidence interval at 95%; mean difference negative values indicate an increase 
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